Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 25078879 | HLA-DR (HLA-DR) | cardiac arrest | NA | NA | NA | positive | |
| patients after cardiac arrest have a modest systemic inflammatory response compared to healthy controls, associated with lower hla-dr expression and attenuated immune response to gram-negative and gram-positive antigens, the latter indicative of an impaired immune response to bacteria. | |||||||
| 24580131 | HLA-DR (HLA-DR) | spiradenoma | NA | NA | NA | unclassified | |
| immunohistochemistry of cd1a, cd3, cd4, cd8, cd56, cd68, intercellular adhesion molecule-1 (icam-1), and hla-dr, as well as double-immunofluorescence labeling of s100 protein/cd1a and cd1a/cd3, was performed using paraffin-embedded specimens from five cases of spiradenoma retrospectively. | |||||||
| 24669841 | HLA-DR (HLA-DR) | aspergillus infections | NA | NA | NA | unclassified | |
| recombinant ifn-g treatment in patients with invasive candida and/or aspergillus infections partially restored immune function, as characterized by an increased hla-dr expression in those patients with a baseline expression below 50%, and an enhanced capacity of leukocytes from treated patients to produce proinflammatory cytokines involved in antifungal defence. | |||||||
| 24709785 | HLA-G (HLA-G) | missed abortions | NA | NA | NA | unclassified | |
| maternal serum soluble hla-g levels in missed abortions. | |||||||
| 24777206 | HLA (HLA) | needle sticks | NA | NA | NA | negation | |
| of the 119 family members, 76% perceived there was no choice in the decision to hla-type siblings; 77% perceived no choice in sibling donation; 86% had no concerns about typing other than needle sticks; and 64% had no concerns about donation. | |||||||
| 24859344 | HLA (HLA) | hantavirus infections | NA | NA | NA | unclassified | |
| several class i and class ii hla haplotypes were linked with severe or benign hantavirus infections, and these haplotypes varied among localities and hantaviruses. | |||||||
| 24916508 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | hematological neoplasms | NA | NA | NA | unclassified | |
| the best donor for a related donor for a human leukocyte antigen (hla) haplotype-mismatched transplant for hematological neoplasms is controversial. | |||||||
| 24916508 | HLA (HLA) | hematological neoplasms | NA | NA | NA | unclassified | |
| our data indicate which hla haplotype-mismatched related donors are associated with the best transplant outcomes in persons with hematological neoplasms. | |||||||
| 24935722 | HLA-A*02 | smoldering multiple myeloma | NA | NA | NA | only_studied | |
| we evaluated a cocktail of hla-a2-specific peptides including heteroclitic xbp1 us184-192 (yispwilav), heteroclitic xbp1 sp367-375 (ylfpqlisv), native cd138260-268 (glvglifav) and native cs1239-247 (slfvlglfl), for their ability to elicit multipeptide-specific cytotoxic t lymphocytes (mp-ctls) using t cells from smoldering multiple myeloma (smm) patients. | |||||||
| 25028821 | HUMAN LEUKOCYTE ANTIGEN (HUMAN LEUKOCYTE ANTIGEN) | composite tissue allotransplantation | NA | NA | NA | unclassified | |
| donor-recipient human leukocyte antigen matching practices in vascularized composite tissue allotransplantation: a survey of major transplantation centers. | |||||||
Copyright 2024